• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Allergan touts 5-year data for Liletta intrauterine contraceptive

May 1, 2018 By Sarah Faulkner

Allergan, Medicines360Allergan (NYSE:AGN) and its nonprofit partner, Medicines360, touted five-year data today from an on-going pivotal trial of its intrauterine device, Liletta.

The levonorgestrel-releasing contraceptive is approved in the U.S. to be used to prevent pregnancy for up to four years.

The companies collected data from women who ranged from 16 – 45 years old. Two women, or 0.1% of study participants, experienced perforation following placement of the device and both were diagnosed within one year. Pelvic infection was found in 11 women and expulsion was reported in 63 participants, Allergan reported.

Just 2.3% of women discontinued use due to bleeding complaints over the course of five years.

The results of the five-year study were presented at this year’s meeting of the American College of Obstetricians and Gynecologists.

“We are encouraged by the presentation today at ACOG, which represents the data from our ongoing clinical trial used in our recent submission to the FDA requesting approval of Liletta for up to five years of use. This will, in turn, help us deliver on our mission of providing appropriate women of all socioeconomic levels the option of an effective long-acting reversible contraception,” Medicines360 CEO Dr. Jessica Grossman said in prepared remarks.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat, Women's Health Tagged With: Allergan, Medicines360

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS